Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Chinese Academy of Medical Sciences & Peking Union Medical College · Chinese PLA General Hospital · +36 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
580
total citations
- FWCI
- 73.41
- Percentile
- 100%
- References
- 31
Citations per year
Authors
47Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Clinical endpoint
- Docetaxel
- Chemotherapy
- Performance status
- Randomization
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.